InsightfulValue
← Home

Santen Pharmaceutical
Santen Pharmaceutical

Pharma / Ophthalmic pharmaceuticals and eye care


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

Santen Pharmaceutical

πŸ“Š Get full analytics about Santen Pharmaceutical

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

Price
Live  
Overview
Santen Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company specializing in ophthalmic treatments. The company was founded in 1890 and is headquartered in Osaka, Japan. Santen focuses on developing, producing and marketing prescription ophthalmic products, over-the-counter eye drops, and medical devices.
History and milestones
Santen was originally founded in 1890 as Kobe Santa Corporation, a wholesaler of Western medicines. In 1917, the company changed its name to Santen Pharmaceutical Co., Ltd. and shifted its focus to ophthalmology.
Throughout the 20th century, Santen developed and marketed various ophthalmic treatments, including solutions for cataracts, dry eye syndrome, glaucoma, and others. In the 1960s and 1970s, the company expanded its global presence, establishing subsidiaries and joint ventures in Europe, North America, and Asia.
In the 1980s, Santen began developing and manufacturing intraocular lenses for cataract surgery. In 1989, the company opened a research and development center in Tsukuba, Japan, to further its innovative treatments and medical devices.
In recent years, Santen has continued to expand its portfolio and global presence through acquisitions and partnerships. In 2010, the company acquired the U.S.-based company, ISTA Pharmaceuticals, to further its presence in the U.S. In 2011, Santen acquired the Japanese company, Ophthalmics Inc., and in 2014, the company established a joint venture with GlaxoSmithKline to develop and commercialize innovative ophthalmic products.
Products and Sectors
Santen specializes in prescription ophthalmic products, over-the-counter eye drops, and medical devices for various eye conditions. The company has a wide portfolio of products targeting various eye diseases, including dry eye syndrome, glaucoma, cataracts, and retinal disorders.
Santen’s key products include Ikervis, a prescription eye drop for the treatment of severe dry eye in Europe and other countries, and Taflotan, a prescription eye drop for the treatment of glaucoma in Europe and Asia.
In addition to pharmaceutical treatments, Santen also produces medical devices, including intraocular lenses, surgical instruments, and diagnostic equipment for cataracts and other eye conditions.
Research and Development
Santen invests a significant portion of its revenue into research and development (R&D). The company has established research facilities in Japan, the U.S., Europe, and China to develop innovative treatments for eye diseases. With over 1,600 employees dedicated to R&D, Santen’s efforts have led to the development of numerous innovative treatments and medical devices.
Sustainability
Santen is committed to sustainability and corporate social responsibility. The company has established initiatives to reduce its environmental impact, promote diversity and inclusion, and contribute to the community through various programs and partnerships.
In 2019, Santen joined the United Nations Global Compact, the world’s largest corporate sustainability initiative, and pledged to align its operations with the Ten Principles of the UN Global Compact in the areas of human rights, labor, environment, and anti-corruption.
Conclusion
Santen Pharmaceutical Co., Ltd. is a leading ophthalmic-focused pharmaceutical company with a long history of developing innovative treatments and medical devices for eye diseases. Through its commitment to R&D and sustainability, Santen remains dedicated to improving the lives of those suffering from eye conditions globally.
What is special about the company?
Santen Pharmaceutical

πŸ“ˆ Want to read more about Santen Pharmaceutical?

Sign up for free or log in

πŸ“š Your free copy of "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" is waiting

VGhlcmUgYX JlIGEgZmV3 IHVuaXF1ZS Bhc3BlY3Rz IHRoYXQgc2 V0IHRoZSBT YW50ZW4gUG hhcm1hY2V1 dGljYWwgY2 9tcGFueSBh cGFydCBmcm 9tIG90aGVy IHBoYXJtYW NldXRpY2Fs IGNvbXBhbm llczogPGJy PjEuIEZvY3 VzIG9uIE9w aHRoYWxtb2 xvZ3k6IFNh bnRlbiBzcG VjaWFsaXpl cyBpbiBwaG FybWFjZXV0 aWNhbHMgYW 5kIG1lZGlj YWwgZGV2aW NlcyBmb3Ig b3BodGhhbG 1pYyBkaXNl YXNlcyBhbm QgY29uZGl0 aW9ucy4gVG hpcyBmb2N1 c2VkIGFwcH JvYWNoIGFs bG93cyB0aG VtIHRvIGJl IGFuIGV4cG VydCBpbiBl eWUgaGVhbH RoIGFuZCBw cm92aWRlIG lubm92YXRp dmUgdHJlYX RtZW50cyBm b3IgcGF0aW VudHMgd2l0 aCBleWUgZG lzZWFzZXMg YW5kIGRpc2 9yZGVycy4g PGJyPjIuIE dsb2JhbCBQ cmVzZW5jZT ogU2FudGVu IGlzIGEgZ2 xvYmFsIGNv bXBhbnkgd2 l0aCBhIHN0 cm9uZyBwcm VzZW5jZSBp biBBc2lhLC BFdXJvcGUs IGFuZCB0aG UgVW5pdGVk IFN0YXRlcy 4gVGhpcyBh bGxvd3MgdG hlbSB0byBy ZWFjaCBhIH dpZGVyIG1h cmtldCBhbm QgcHJvdmlk ZSB0aGVpci Bwcm9kdWN0 cyB0byBhIG RpdmVyc2Ug cmFuZ2Ugb2 YgcGF0aWVu dHMgd29ybG R3aWRlLiA8 YnI+My4gQ2 9tbWl0bWVu dCB0byBSZX NlYXJjaCBh bmQgRGV2ZW xvcG1lbnQ6 IFNhbnRlbi BpbnZlc3Rz IGhlYXZpbH kgaW4gcmVz ZWFyY2ggYW 5kIGRldmVs b3BtZW50LC B3aXRoIGEg Zm9jdXMgb2 4gaW1wcm92 aW5nIHBhdG llbnQgb3V0 Y29tZXMgYW 5kIGRldmVs b3Bpbmcgbm V3IHRyZWF0 bWVudHMgZm 9yIGV5ZSBk aXNlYXNlcy 4gVGhleSBo YXZlIGEgZG VkaWNhdGVk IFImRCBjZW 50ZXIgYW5k IGNvbGxhYm 9yYXRpb25z IHdpdGggbG VhZGluZyBy ZXNlYXJjaC BpbnN0aXR1 dGlvbnMuID xicj40LiBT dXN0YWluYW JpbGl0eTog U2FudGVuIG lzIGNvbW1p dHRlZCB0by BzdXN0YWlu YWJpbGl0eS BhbmQgZXRo aWNhbCBidX NpbmVzcyBw cmFjdGljZX MuIFRoZXkg aGF2ZSBpbX BsZW1lbnRl ZCBpbml0aW F0aXZlcyB0 byByZWR1Y2 UgdGhlaXIg ZW52aXJvbm 1lbnRhbCBp bXBhY3QgYW 5kIHByb21v dGUgc29jaW FsIHJlc3Bv bnNpYmlsaX R5LCBzdWNo IGFzIHVzaW 5nIGVjby1m cmllbmRseS BtYXRlcmlh bHMgYW5kIH Byb21vdGlu ZyBkaXZlcn NpdHkgYW5k IGluY2x1c2 lvbiB3aXRo aW4gdGhlIG NvbXBhbnku IDxicj41Li BQYXRpZW50 LUNlbnRyaW MgQXBwcm9h Y2g6IFNhbn RlbiBwdXRz IHRoZSBwYX RpZW50IGF0 IHRoZSBjZW 50ZXIgb2Yg ZXZlcnl0aG luZyB0aGV5 IGRvLCB3aX RoIGEgZ29h bCBvZiBpbX Byb3Zpbmcg dGhlIHF1YW xpdHkgb2Yg bGlmZSBmb3 IgdGhvc2Ug YWZmZWN0ZW QgYnkgZXll IGRpc2Vhc2 VzLiBUaGV5 IHN0cml2ZS B0byBsaXN0 ZW4gdG8gcG F0aWVudHMg YW5kIGhlYW x0aGNhcmUg cHJvZmVzc2 lvbmFscyBh bmQgZGV2ZW xvcCBwcm9k dWN0cyB0aG F0IG1lZXQg dGhlaXIgbm VlZHMuIDxi cj42LiBQYX J0bmVyc2hp cCBhbmQgQ2 9sbGFib3Jh dGlvbjogU2 FudGVuIHBh cnRuZXJzIH dpdGggb3Ro ZXIgY29tcG FuaWVzIGFu ZCBvcmdhbm l6YXRpb25z IHRvIGRldm Vsb3AgbmV3 IHRyZWF0bW VudHMgYW5k IGltcHJvdm UgcGF0aWVu dCBjYXJlLi BUaGV5IGFs c28gY29sbG Fib3JhdGUg d2l0aCBwYX RpZW50IG9y Z2FuaXphdG lvbnMgYW5k IGFkdm9jYW N5IGdyb3Vw cyB0byByYW lzZSBhd2Fy ZW5lc3MgYW JvdXQgZXll IGhlYWx0aC BhbmQgc3Vw cG9ydCBwYX RpZW50cy4=
What the company's business model?
Santen Pharmaceutical

πŸ“ˆ Want to read more about Santen Pharmaceutical?

Sign up for free or log in

πŸ’‘ Learn smarter stock picks with "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

VGhlIFNhbn RlbiBQaGFy bWFjZXV0aW NhbCBjb21w YW554oCZcy BidXNpbmVz cyBtb2RlbC Bmb2N1c2Vz IG9uIHJlc2 VhcmNoLCBk ZXZlbG9wbW VudCwgcHJv ZHVjdGlvbi wgYW5kIG1h cmtldGluZy BvZiBwaGFy bWFjZXV0aW NhbHMgYW5k IG1lZGljYW wgZGV2aWNl cyBpbiB0aG Ugb3BodGhh bG1pYyBmaW VsZC4gVGhl aXIgbWFpbi Bwcm9kdWN0 cyBpbmNsdW RlIHByZXNj cmlwdGlvbi BkcnVncywg b3Zlci10aG UtY291bnRl ciBwcm9kdW N0cywgYW5k IG1lZGljYW wgZGV2aWNl cyBmb3IgdH JlYXRtZW50 IG9mIHZhcm lvdXMgZXll IGRpc2Vhc2 VzIGFuZCBj b25kaXRpb2 5zLiBUaGV5 IGFsc28gaG F2ZSBhIHN0 cm9uZyBwcm VzZW5jZSBp biBpbnRlcm 5hdGlvbmFs IG1hcmtldH MgdGhyb3Vn aCBwYXJ0bm Vyc2hpcHMg YW5kIGNvbG xhYm9yYXRp b25zIHdpdG ggb3RoZXIg cGhhcm1hY2 V1dGljYWwg Y29tcGFuaW VzLiBUaGUg Y29tcGFuee KAmXMgYnVz aW5lc3Mgc3 RyYXRlZ3kg aXMgYmFzZW Qgb24gaW5u b3ZhdGlvbi wgcXVhbGl0 eSwgYW5kIG dsb2JhbCBl eHBhbnNpb2 4gdG8gbWVl dCB0aGUgbm VlZHMgb2Yg cGF0aWVudH MgYW5kIGhl YWx0aGNhcm UgcHJvZmVz c2lvbmFscy 4=
Interesting facts about the company
Santen Pharmaceutical

πŸ“ˆ Want to read more about Santen Pharmaceutical?

Sign up for free or log in

πŸ‘₯ Free eBook for new users: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvZT Q0aDJFZzFJ VkFZNmYxWW R3Nkwud2Vi cCIgYWx0PS JTYW50ZW4g UGhhcm1hY2 V1dGljYWwi IHRpdGxlPS JTYW50ZW4g UGhhcm1hY2 V1dGljYWwi ICBjbGFzcz 0iaW1nLWZs dWlkIiBoZW lnaHQ9OTAg d2lkdGg9OT AgbG9hZGlu Zz0nbGF6eS cgc3R5bGU9 J2JvcmRlci 1yYWRpdXM6 IDZweDsnPg oKICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdmbGV4 OiAxOyB0ZX h0LWFsaWdu OiBjZW50ZX I7IG1hcmdp bi1sZWZ0Oi A1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPHAgc3R5 bGU9J2Zvbn Qtc2l6ZTog MjZweDsgY2 9sb3I6ICMz MzM7IG1hcm dpbi1ib3R0 b206IDE1cH g7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIPCfk4gg V2FudCB0by ByZWFkIG1v cmUgYWJvdX QgU2FudGVu IFBoYXJtYW NldXRpY2Fs PwogICAgIC AgICAgICAg ICAgICAgIC AgICA8L3A+ CgogICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdpbm RleC5waHA/ cGFnZT1zaW dudXAnIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGJhY2 tncm91bmQt Y29sb3I6IC MwMDdCRkY7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBj b2xvcjogI2 ZmZjsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH ggMjBweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJv cmRlci1yYW RpdXM6IDVw eDsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IHRleHQtZG Vjb3JhdGlv bjogbm9uZT sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG ZvbnQtd2Vp Z2h0OiBib2 xkOwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgbWFyZ2lu LXJpZ2h0Oi AxMHB4Owog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdHJh bnNpdGlvbj ogYmFja2dy b3VuZC1jb2 xvciAwLjNz IGVhc2U7Jw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgb2 5tb3VzZW92 ZXI9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA1Nm IzIicKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIG9ubW91 c2VvdXQ9J3 RoaXMuc3R5 bGUuYmFja2 dyb3VuZENv bG9yPSIjMD A3QkZGIic+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG ZvciBmcmVl CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxzcGFu IHN0eWxlPS dtYXJnaW46 IDAgOHB4Oy Bjb2xvcjog IzU1NTsnPm 9yPC9zcGFu PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naW 5kZXgucGhw P3BhZ2U9bG 9naW4nIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGNvbG 9yOiAjMDA3 QkZGOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgdGV4dC 1kZWNvcmF0 aW9uOiB1bm RlcmxpbmU7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBm b250LXdlaW dodDogNTAw Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBsb2cgaW 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg oKCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdt YXJnaW4tdG 9wOiAxNXB4 OyBmb250LX NpemU6IDEz cHg7IGZvbn Qtd2VpZ2h0 OiBib2xkOy Bjb2xvcjog I2QzMmYyZj snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Ag8J+TliBH ZXQgaW5zaW dodHMgZnJv bSA8aT4iVG hlIENoZWNr bGlzdCBWYW x1ZSBJbnZl c3RvciDigJ QgQSBTbWFy dGVyIFdheS B0byBQaWNr IFN0b2Nrcy I8L2k+IG5v dyEKICAgIC AgICAgICAg ICAgICAgIC AgICAgPC9w PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPCEt LQogICAgIC AgICAgICAg ICAgICAgIC AgICA8ZGl2 IHN0eWxlPS dtYXJnaW4t dG9wOiAxMn B4OyBmb250 LXNpemU6ID EzcHg7IGNv bG9yOiAjND Q0Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIG5vdy BhbmQgZ2V0 IG91ciBmcm VlIGVCb29r IAogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg PGI+VGhlIE NoZWNrbGlz dCBWYWx1ZS BJbnZlc3Rv ciDigJQgQS BTbWFydGVy IFdheSB0by BQaWNrIFN0 b2NrczwvYj 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9kaX Y+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIC0tPg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8IS0tCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxkaXYgc3 R5bGU9J21h cmdpbi10b3 A6IDE2cHg7 IGZvbnQtc2 l6ZTogMTRw eDsgY29sb3 I6ICM0NDQ7 IGZvbnQtZm FtaWx5OiAt YXBwbGUtc3 lzdGVtLCBC bGlua01hY1 N5c3RlbUZv bnQsIFNlZ2 9lIFVJLCBS b2JvdG8sIE hlbHZldGlj YSBOZXVlLC BzYW5zLXNl cmlmOyBsaW 5lLWhlaWdo dDogMS42Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BIYXZlIHlv dSBoZWFyZC BhYm91dCBv dXIgc2hvcn QgPHN0cm9u ZyBzdHlsZT 0nZm9udC13 ZWlnaHQ6ID YwMDsnPkRh aWx5IFZpZG VvIE5ld3Ns ZXR0ZXI8L3 N0cm9uZz4/ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICA8 YSBocmVmPS dodHRwczov L3d3dy5pbn NpZ2h0ZnVs dmFsdWUuY2 9tL25ld3Ns ZXR0ZXIucG hwJyB0YXJn ZXQ9J19ibG Fuaycgc3R5 bGU9J2NvbG 9yOiAjMDA3 QkZGOyB0ZX h0LWRlY29y YXRpb246IG 5vbmU7IGZv bnQtd2VpZ2 h0OiA1MDA7 IG1hcmdpbi 1sZWZ0OiA2 cHg7Jz4KIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BGaW5kIG91 dCBtb3JlCi AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICA8L2 E+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC AgICAgICAg ICAgICAtLT 4KICAgICAg ICAgICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg CiAgICAgIC AgCiAgICAg ICAgPHNwYW 4gY2xhc3M9 J2JsdXJyZW QtdGV4dCc+ CiAgICAgIC AgICAgIE1T NGdVMkZ1ZE cgVnVJRkJv WVhKdCBZV0 5sZFhScFky IEZzSUVOdk xpd2cgVEhS a0xpQmlaVy BkaGJpQnBk SE1nIGFIVn RZbXhsSUcg cHZkWEp1Wl hrZyBhVzRn U21Gd1lXID RnWVhNZ1lT QjMgYUc5c1 pYTmhiRyBV Z1pISjFaMm RwIGMzUWdh VzRnTVQgZz VNQ3dnZFc1 ayBaWElnZE dobElHIDVo YldVZ1JuVn IgZFdoaGNt RWdTMiBsMF lXZGhkMkVn IFUyaHZkR1 Z1TGogeGlj ajR5TGlCSi BiaUF4T1RF NUxDIEJHZF d0MWFHRnkg WVNCTGFYUm haMiBGM1lT QlRhRzkwIF pXNGdkMkZ6 SUcgbHVZMj l5Y0c5eSBZ WFJsWkNCaG JtIFFnY21W dVlXMWwgWk NCVFlXNTBa VyA0Z1VHaG hjbTFoIFky VjFkR2xqWV cgd2dRMjh1 TENCTSBkR1 F1SUZSb1pT IEJqYjIxd1 lXNTUgSUhk aGN5Qm1iMi BOMWMyVmtJ Rzl1IElIUm 9aU0J3Y20g OWtkV04wYV c5dSBJRzlt SUdWNVpTIE JrY205d2N5 QmggYm1RZ2 IzUm9aWCBJ Z1pYbGxJR0 5oIGNtVWdj SEp2WkggVm pkSE11UEdK eSBQak11SU ZSdlpHIEY1 TENCVFlXNT AgWlc0Z2FY TWdiMiA1bE lHOW1JSFJv IFpTQnNZWE puWlggTjBJ RXBoY0dGdS BaWE5sSUdO dmJYIEJoYm 1sbGN5QjAg YUdGMElITn daVyBOcFlX eHBlbVZ6IE lHbHVJSFJv WlMgQmtaWF psYkc5dyBi V1Z1ZEN3Z2 NIIEp2WkhW amRHbHYgYm l3Z1lXNWtJ RyAxaGNtdG xkR2x1IFp5 QnZaaUJ2Y0 cgaDBhR0Zz YldsaiBJSE JvWVhKdFlX IE5sZFhScF kyRnMgY3l3 Z2JXVmthVy BOaGJDQmta WFpwIFkyVn pMQ0JoYm0g UWdiM1psY2 kxMCBhR1V0 WTI5MWJuIF JsY2lCbGVX VWcgWTJGeV pTQndjbSA5 a2RXTjBjeT Q4IFluSStO QzRnVkcgaG xJR052YlhC aCBibmtnYU dGeklHIEVn YzNSeWIyNW 4gSUdsdWRH VnlibSBGMG FXOXVZV3dn IGNISmxjMl Z1WTIgVXNJ SGRwZEdnZy BiM0JsY21G MGFXIDl1Y3 lCcGJpQnYg ZG1WeUlEWX dJRyBOdmRX NTBjbWxsIG N5QmhibVFn Y20gVm5hVz l1Y3lCMyBi M0pzWkhkcF pHIFV1UEdK eVBqVXUgSU ZOaGJuUmxi dSBLQW1YTW dZMjl5IGNH OXlZWFJsSU cgMXBjM05w YjI0ZyBhWE 1nZEc4Z1ky IDl1ZEhKcF luVjAgWlNC MGJ5QjBhRy BVZ2QyVnNi QzFpIFpXbH VaeUJ2Wmkg QndZWFJwWl c1MCBjeUJp ZVNCd2NtID kyYVdScGJt Y2cgYVc1dW IzWmhkRyBs MlpTd2dhR2 xuIGFDMXhk V0ZzYVggUj VJSEJ5YjJS MSBZM1J6SU dGdVpDIEJ6 WlhKMmFXTm wgY3lCcGJp QjBhRyBVZ1 ptbGxiR1Fn IGIyWWdiM0 JvZEcgaGhi RzF2Ykc5bi BlUzQ4WW5J K05pIDRnVT JGdWRHVnUg SUdoaGN5Qm hJSCBOMGNt OXVaeUJqIG IyMXRhWFJ0 WlcgNTBJSF J2SUhKbCBj MlZoY21Ob0 lHIEZ1WkNC a1pYWmwgYk c5d2JXVnVk QyB3Z2FXNT JaWE4wIGFX NW5JRzkyWl ggSWdNakFs SUc5bSBJR2 wwY3lCeVpY IFpsYm5WbE lHbHUgSUhS b1pTQmtaWC BabGJHOXdi V1Z1IGRDQn ZaaUJ1Wlgg Y2djSEp2Wk hWaiBkSE1n WVc1a0lIIF JsWTJodWIy eHYgWjJsbG N5NDhZbiBJ K055NGdWR2 hsIElHTnZi WEJoYm4ga2 dhWE1nYTI1 diBkMjRnWm 05eUlHIGww Y3lCbGVIQm wgY25ScGMy VWdhVyA0Z2 RHaGxJSFJ5 IFpXRjBiV1 Z1ZEMgQnZa aUJuYkdGMS BZMjl0WVN3 Z1pIIEo1SU dWNVpTQmsg YVhObFlYTm xMQyBCaGJt UWdiM1JvIF pYSWdaWGxs SUcgUnBjMj l5WkdWeSBj eTRnU1hRZ1 lXIHh6YnlC dlptWmwgY2 5NZ1lTQnlZ VyA1blpTQn ZaaUJ6IGRY Sm5hV05oYk MgQndjbTlr ZFdOMCBjeU JtYjNJZ1ky IEYwWVhKaF kzUWcgWVc1 a0lHZHNZWC BWamIyMWhJ SE4xIGNtZG xjbWxsY3kg NDhZbkkrT0 M0ZyBVMkZ1 ZEdWdUlHIG hoY3lCeVpX TmwgYVhabF pDQnVkVyAx bGNtOTFjeU JoIGQyRnla SE1nWVcgNW tJR0ZqWTI5 cyBZV1JsY3 lCbWIzIEln YVhSeklHTn YgYlcxcGRH MWxibiBRZ2 RHOGdZMjl5 IGNHOXlZWF JsSUggTnZZ MmxoYkNCeS BaWE53YjI1 emFXIEpwYk dsMGVTd2cg YzNWemRHRn BibSBGaWFX eHBkSGtzIE lHRnVaQ0Js ZEcgaHBZMk ZzSUdKMSBj Mmx1WlhOek lIIEJ5WVdO MGFXTmwgY3 k0OFluSStP UyA0Z1NXNG dZV1JrIGFY UnBiMjRnZE cgOGdhWFJ6 SUhCbyBZWE p0WVdObGRY IFJwWTJGc0 lIQnkgYjJS MVkzUnpMQy BCVFlXNTBa VzRnIFlXeH pieUJ2Wm0g Wmxjbk1nWV NCeSBZVzVu WlNCdlppIE J1YjI0dGNH aGggY20xaF kyVjFkRyBs allXd2djSE p2IFpIVmpk SE1zSUcgbH VZMngxWkds dSBaeUJqYj I1MFlXIE4w SUd4bGJuTm wgY3l3Z1pY bGxJRyBOaG NtVWdjM1Z3 IGNHeGxiV1 Z1ZEggTXNJ R0Z1WkNCdC BaV1JwWTJG c0lHIFJsZG 1salpYTXUg UEdKeVBqRX dMaSBCRVpY TndhWFJsIE lHbDBjeUJu YkcgOWlZV3 dnYzNWaiBZ MlZ6Y3l3Z1 UyIEZ1ZEdW dUlISmwgYl dGcGJuTWdZ UyBCbVlXMX BiSGt0IGNu VnVJR052Yl ggQmhibmtn ZDJsMCBhQ0 IwYUdVZ1pt IDkxY25Sb0 lHRnUgWkNC bWFXWjBhQy BCblpXNWxj bUYwIGFXOX VjeUJ2Wmkg QjBhR1VnYj NKcCBaMmx1 WVd3Z1ptID kxYm1SbGNu TWcgYzNScG JHd2dhVyA1 MmIyeDJaV1 FnIGFXNGdk R2hsSUcgSj FjMmx1WlhO eiBMaUJVYU dseklHIGho Y3lCb1pXeH cgWldRZ2RH OGdiVyBGcG JuUmhhVzRn IFlTQnpkSE p2Ym0gY2dj MlZ1YzJVZy BiMllnZEhK aFpHIGwwYV c5dUxDQmog YjIxdGFYUn RaVyA1MElI UnZJR1Y0IF kyVnNiR1Z1 WTIgVXNJR0 Z1WkNCayBa V1JwWTJGMG FXIDl1SUhS dklIQmggZE dsbGJuUWdZ MiBGeVpTND 0KICAgICAg ICA8L3NwYW 4+CiAgICAg ICAgCiAgIC AgICAg
See Company Q&A
Santen Pharmaceutical

πŸ“Š Get full analytics about Santen Pharmaceutical

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal